Peijia Medical (HKG:9996) forecasts its 2024 revenue to surge by 38% to 43% year-over-year to between 610 million yuan and 630 million yuan.
The surge is attributable to growth in the medical equipment company's neuro-interventional product lines and a greater share in the Chinese transcatheter aortic valve replacement market, according to a Monday filing with the Hong Kong Exchange.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.